Friday, 14 October 2016

GA4GH: What? Why? How?

In August 2016, I was offered the position of Chair of the Global Alliance for Genomics and Health (GA4GH), and am delighted to accept. To give a little more background to the announcement going out today, and to provide some answers to personal questions, I’ve written a bit of Q&A.

In this post I answer the three questions I am most frequently asked about the GA4GH, namely: What on Earth is it? Why am I becoming Chair? And how on earth do I find the time for these things?

What is the Global Alliance for Genomics and Health?

The GA4GH is producing solutions for sharing genomic and clinical data responsibly. Low-cost, high-throughput sequencing has changed – and is still changing – the way we understand living things, from the basic science of life to human disease. Healthcare is a big focal point for this change and, now that there is a critical mass of knowledge about the path from personal sequence to treatment decisions, is able to embrace routine sequencing of patient genomes and other molecular measurements.

But if we want a future in which all people can benefit from this change, we need to solve a number of technical, structural, security and ethical problems. The Global Alliance for Genomics and Health was set up to to do just that.

At present, my overall impression of GA4GH is of a professional orchestra warming up: intense, but disjointed, activity and passion. The different sections are poised to work together, producing an ecosystem of harmonised technical and ethical standards.

How we measure

Over the next decade, healthcare will begin to change the way it collects molecular measurements from patients. 'Genomics entering the clinic' means that it will soon become a matter of routine to gather DNA, RNA, protein and metabolite data from patients, along with traditional information. (Note: I like to use ‘Genomics’ in a broad sense, encompassing DNA, RNA, protein and metabolite measurement, partly because terms like ‘omics' and ‘multiomics’ are clumsy and don't translate well beyond the field).

Incorporating new measurements is not new to healthcare: for example, blood biochemistry has been a mainstay in medical practice for over 50 years, and clinical genetics has been used to successfully diagnose millions of people in recent decades. Oncologists routinely use the presence or absence of specific genetic loci in certain tumours to guide treatment.

I think it is generally accepted that these more narrow, field-specific measurements of genomics will change to become a more comprehensive, routine collection of many molecular aspects at the same time, applicable to many areas of healthcare.

Genomes, whole-blood transcriptomes, tumour RNA-seq and large scale-metabolomics can all provide relevant information that is useful in assessing individuals, and still more useful when analysed collectively.

A game-changing opportunity

This is all a bit hairy in terms of skills transfer and capacity, but it’s much more exciting in terms of opportunity.

The consequence of this is that healthcare, a massive chunk of the world economy (between 8% and 20% of GDP in developed-world economies) is going to be conducting high-throughput molecular phenotyping on humans – a wonderful,outbred mammal.

From the perspective of research, which has traditionally looked to other organisms to understand how they work before translating that knowledge to humans, this is an amazing opportunity. Being able to use human data directly – particularly by gathering the huge datasets generated in routine healthcare – will be transformative for science.

The sheer ‘firepower’ of healthcare means humans will be the most studied organism on the planet. No other animal will come close in terms of scale, detail and longitudinal sampling. What an opportunity for research – both basic and applied!

Turbulent waters

Repurposing healthcare data for research, at scale, will not be smooth sailing. There are real cross currents around data, with different levels of access and rules of engagement buffeting one another.

Fundamentally, much of molecular biology research data is fully open, globally aggregated (e.g. ENA/GenBank, PDB, the Human Genome) or, in the case of human research subjects, distributed in accordance with different consents that patients have signed.

Healthcare data is completely different. There is a thicket of national legislation, each rooted deeply in national law, language and societal norms, and the primary remit of each system is to keep its citizens healthy – not to create resources for research.

As generating molecular data becomes more a matter of routine, the constraints for access will doubtless change, perhaps without reference to research and its potential to create better long-term solutions.

Another interesting driver for change is patient engagement. Increasingly, clinical research has become more of a two-way relationship, with patients empowered to be owners of their personal measurement data, in addition to being donors.

Even assuming that all goes well and access issues are resolved, there is the matter of handling data on massive scales, and being equipped to analyse it. Engineering around large-scale genomic data is no trivial matter. One can’t simply slurp up spreadsheets or STATA frames of genomes, transcriptomes and metabolomes – you need proper computational muscle.

There is also the opposite 'knowledge flow': for healthcare to leverage genomics well, there are many practical problems for which research holds the solutions. We need these solutions and skills to flow from basic research into healthcare.

If we want a future in which we can all benefit from our investment in studying humans on the molecular level, we need to solve these problems.

The major challenges, in a nutshell

Technical problems require solutions for working with data on different scales in sensible, portable ways.

Structural problems can be resolved when we agree on how to represent reference data. That includes, for example, genomes and variants, but also the way we describe things. The meta-data must be aligned to allow the transmission of key clinical data, and to allow data sharing more broadly.

(The devil is in the detail here. Consider the many ways one could represent ‘nested variation’ – a single nucleotide polymorphism on a structural insertion of DNA in the context of an inversion – something we elide over in both research and clinical practice.)

Ethical and regulatory problems are perhaps the most discussed across the board, and we must find a way for bona fide researchers to access data within an appropriate framework, globally.

Security problems require tight coordination. The GA4GH aims to establish a federation in which datasets are appropriately accessible. That means we need access tools like APIs and virtualisation schemes that can work smoothly, with predominantly secure electronic methods, and absolute clarity and constant forward thinking about security.

But as with all complex issues, many of the challenges are some kind of combination of problems, or hide in the spaces in between.

GA4GH: an ambitious endeavour

Resolving so many challenges in a relatively short time is certainly ambitious, but it can be achieved. It isn’t easy technically or socially, because it will only be effective if it is global. But we know from experience that it isn’t impossible. 

The extensive work done already shows that it is tractable: for example we already share (mainly by data transfer) large cohorts of patients for joint analysis delivering many new insights.

We have established appropriate ethical access to these schemes. We have also demonstrated, in specific areas, that federation can work (e.g. MatchMaker Exchange for rare disease patient discovery) and that virtualisation is an effective approach (e.g. PanCancer Analysis). 

Many academic and commercial groups in the GA4GH already provide practical solutions, but they are not as well coordinated as they should be.

The goal of the GA4GH is to enable a future in which secondary use of healthcare-generated genomics data is routine and practical, and we already have a strong start.
We need to make existing ad-hoc schemes better by coming together more.

Why am I Chairing the Global Alliance?

GA4GH has been in operation for three years, led first by David Altschuler (now at Vertex Pharmaceuticals), then by Tom Hudson (now at Abbvie). David and Tom oversaw the establishment of GA4GH and grew it from 90 to 433 partner organisations. Under their leadership the GA4GH set up a series of technical, meta-data, ethical, regulatory and security work streams, many of which have been very successful, if isolated. There have also been a number of exploratory projects set up, though many seem to be driven by curiosity and personal interest.

My goal for the GA4GH over the next three years is to rebalance delivery and structure, building on the partnership’s existing strength of exploratory work. Many people in GA4GH, and some outside the Alliance, are eager to see more alignment, and there is an incredible pool of talent in engineering, genomics, clinical and ethics, all ready to come together around this.

We may not be able to solve every challenge, as many of these eventually merge with healthcare informatics generally. But I am confident that we will make substantial progress and achieve a far better world for both healthcare and research.

Where do I find time for these things?

(No, I do not have a Time-Turner.)

When people who know me heard that I took on another leadership role, they rolled their eyes and either berated me for not saying no, or simply asked how on Earth I will balance this with my other responsibilities.

I am stretched a bit thin, between my leadership roles at EMBL-EBI, ELIXIR and Genomics England, my consultancy for Oxford Nanopore and GSK and my advisory role for other organisations, and other professional responsibilities. Importantly, I also have a life outside of science: I am a Dad with two children and a wonderful wife.

How could I take on being Chair of the GA4GH, with everything else going on? How could I … not?

I am an endlessly curious, optimistic person and love bringing people together to make collaborations work, even if having such diverse commitments requires time slicing, and results in my being distracted. In fact, for the past three years I have been quite active in GA4GH, but at a very technical level. This role is more than just guiding one or two working groups.

Team work

Working in teams – tight or loose – and in close partnership is my default strategy, in both work and family life. My wife and I are very much equitable partners, with demanding careers and full-time jobs. We are both responsible for making sure the logistics work (and that we have backup plans), and for setting aside quality time with our children. That said, one of the drawbacks of being spread thin is that sometimes I will be at home, but completely distracted by work – something that drives the whole family a bit nuts. I know I am not alone in struggling with this. Like many people I feel that I short-change my family, even as they support me completely.

I could not function as Director of EMBL-EBI without Rolf Apweiler as joint Director, and the high level of trust we share. Although we are chalk and cheese (focused, organised German and messy, problem-orientated Brit), our complementarity is a real strength. I also lead EMBL-EBI research in partnership with Nick Goldman, and as a group leader I’ve partnered previously with Ian Dunham and now with Tom Fitzgerald to lead my research projects. I see my roles with Genomics England, Oxford Nanopore and GSK as providing help, support and constructive criticism, but as a consultant my interactions are limited.

Chairing the GA4GH will be a partnership role I share with the Alliance’s strong Executive Director, Peter Goodhand of the Ontario Institute for Cancer Research, who keeps many of the processes working smoothly. We both plan to recruit an active set of Vice-Chairs who will provide a high level of strategic oversight. 

I know there is enough talent in the GA4GH to deliver this.

Enabling talented people to deliver

High-level leadership is mainly about providing the right space and conditions for knowledgeable, talented people to step up and deliver. Being clear about the vision and direction is incredibly important, but setting out a vision often isn’t the most challenging aspect. The hard thing is to identify the people who have the right mindset and skills, and enable them to drive part of the work all the way through to delivery.

I am speaking from experience when I say that this is true for leadership generally, both in formal organisations like EMBL-EBI and more loosely coupled organisations such as GA4GH. The problems we are grappling with cannot be resolved single-handed; rather, we will be able to deliver practical solutions by aligning individuals and groups, and ensuring they have the right balance of skills, enthusiasm, resources and motivation.

No human is an island.

The adventure of understanding things is deeply exciting for me, whether it’s a well-known problem or an unexplored area of science, so the GA4GH is a project after my own heart. As with any ambitious endeavour, there are bound to be arguments and hard decisions of all shapes and sizes in the GA4GH. But the motivation of people to participate, the rewards of collaboration and the potential benefits to society are great.

I am very lucky to be surrounded by supportive, excellent colleagues on every level: the people who manage me, my peers around the world and those I manage. I am also lucky to be working in science, which thrives on collaboration, information exchange and support, and where just being reciprocally nice is an excellent strategy.

Working together, we are going to make the next few years of GA4GH amazing. I cannot wait.


Manuel Corpas said...

I look forward to many great outputs under your leadership

Heni Herbal said...

thanks so much for the information that you provide on this holiday.
Inilah Gejala Penyakit Gagal Ginjal Pada Anak
Penyakit Gagal Ginjal Dan Pengobatannya
Penyebab Leukosit Tinggi
Obat Tradisional Triflex Capsule Green World
Menu Makanan Sehat Untuk Penderita Leukimia

Heni Herbal said...

Zest for lunch today? Thank you for the information
Obat Alami Untuk Meningkatkan Daya Ingat
Pengobatan Alternatif Sakit Maag Secara Tradisional
Pengobatan Alternatif Nyeri Sendi Bahu Tradisional
Pengobatan Alternatif Nyeri Sendi Bahu Tradisional
Obat Tradisional Darah Tinggi

نور الهدى said...

شركات نقل اثاث بالمدينة المنورة تساعدك على نقل اثاثك بامان فلا داعى للقلق مع شركات نقل اثاث بجدة

عزيزى العميل انت من محبى التنقل باستمرار بالتالى انت بحاجة ماسة وضروية الى الاستعانة بالمختصين في نقل العفش خاصة شركات نقل اثاث بالرياض لان الاستعانة باى من عمالة الشوارع الغير مدربة والتي لا تمتلك خبرة كافية في نقل العفش او الحفاظ علية وليس هذا فقط فقد يؤدى الاستعانة بعمالة الشوارع الى حدوث حالة فقدان وتكسير للاثاث بالتالى التاثير الضار عليك عزيزى العميل

لا تقلق مطلقاً الان بشأن نقل اي منقولات خاصة بك طالما استعنت بشركة الاول لـ نقل الأثاث في الرياض وخارج الرياض فنحن ليس الوحيدون ولكننا متميزون عن اى مؤسسة أخرى داخل وخارج الدمام وشهرتنا كافضل شركة نقل عفش بينبع
نقل عفش بجدة

Heni Herbal said...

present information this morning really means a lot to us thanks .
Pengobatan Tradisional Radang Lambung
Obat Kista Duktus Tiroglosus
Ginkgo Biloba Plus Capsule Green World
Pengobatan Alami Hipertensi Paling Mujarab
Cara Menghilangkan Lendir Di Paru-Paru Secara Alami

khaled ali said...

شركة نقل اثاث وعفش بالطائف
شركة تنظيف بالطائف
شركة مكافحة حشرات بالطائف
شركة كشف تسربات المياه بالطائف
شركة رش مبيدات بالطائف
شركة تنظيف خزانات بالطائف

khaled ali said...

Best Company Home Services
شركة رش مبيدات بخميس مشيط
شركة تنظيف بخميس مشيط
شركة تنظيف خزانات بخميس ميشط
شركة كشف تسربات المياه بخميس مشيط
شركة مكافحة حشرات بخميس مشيط
شركة تنظيف منازل بخميس مشيط
شركة نقل اثاث وعفش بخميس مشيط
شركة تسليك مجارى بخميس مشيط
شركة رش مبيدات بالطائف

Hammed said...

I just see the post i am so happy to the communication science post of information's.So I have really enjoyed and reading your blogs for these posts.Any way I’ll be replay for your great thinks and I hope you post again soon...

SEO Company in Chennai

Anil Gupta said...

Thanks for the information. Helped us to convince most on how this process works and what they could achieve by following these guidelines.
Web Designing Company in Bangalore, Web Development Company Bangalore

Aliando Syarief said...

lagu terbaru
gudang lagu
mp3 kpop

Antonio Jefferson Cole said...

My name is Antonio Jefferson Cole, I'm in Salt Lake City, Utah. It is a pleasure for me to write this testimony about how I got healed from genital herpes 12 hours ago. I have read so many comments from some people who have been cured of HIV by Dr. Ekpiku, but I never believed them. I was hurt and depressed, so I was very curious and wanted to try Dr. Ekpiku, so I contacted him on his email when I get in touch with him, he assured me 100% that it will heal me, I begged Him to help me. My treatment was a great success, he healed me as he promised. He sent me his medication and asked me to go for check-up after 2 weeks of taking the medication. I agree with him, I took this medication and went to the check-up after 2 month, to my greatest surprise my result was negative after treatment, I am really happy that I am healed and healthy again. I waited for four months to make sure I was completely healed before writing this testimony. I did another blood test today and was still negative Herpes, so I think its time I tell someone out there with Herpes HSV-1 or HSV-2, HIV, HPV, hepatitis B, diabetes, cancer and so on, Dr. Ekpiku in the email: . Your phone number is +2348073673757, He is also on whats app. I completely understand how you can feel skeptical about it, because it happened to me, it can be expensive for you, but I'm telling you now that there is a cure for these diseases and I am a living witness firsthand.or you can email me on for any assistance.

Prasanth said...

The blog is absolutely truly incredible. Lots of large information and inspiration, both of which we all need.
UI Designing Company in Bangalore, Web Application Development Companies in Bangalore

obat kutil kelamin yang alami said...

There is noticeably a bundle to know about this. I assume you made certain nice points in features also.
Obat Kutil di Batang Zakar
Obat Kutil Di Kemaluan Wanita | Penyakit Kelamin Wanita
Obat Penghilang Kutil Kelamin
Tanda-Tanda Kutil Kelamin Condyloma Acuminata Di Bibir Vagina
obat jengger ayam untuk wanita
Kutil Di Alat Kelamin Serta Cara Menghilangkanya
Obat Kutil Kelamin Tradisional
Obat Kutil Pada Memek | Cara Menyembuhkan Kutil Pada Kemaluan Wanita
Penyembuhan Kutil Di Bibir Vagina | Penyakit Kelamin Kutil
Penyebab Kutil Kelamin dan Cara Penyembuhanya